First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.
Partner with us to speed up the development of a Phase 2 clinical trial-ready second-generation vaccine which induces durable and strong neutralising antibody response through direct investment or licensing.
The innovation
Second-generation COVID-19 vaccine which induces durable and strong neutralising antibody immunity activity against the original Wuhan SARS-CoV-2 strain as well as Beta, Delta and Omicron variants.
Market need
Safe and effective vaccines are critical in controlling the spread of COVID-19, which has claimed more than six million lives. Emerging mutant variants of SARS-CoV-2 are less susceptible to the immunity produced by the first generation COVID-19 vaccines.
Innovation status
The second-generation vaccine targets the receptor-binding domain region of the spike protein, compared to current vaccines that use antigens based on the full-length spike protein. This approach offers potential production and manufacturing advantages including the delivery of abundant, temperature-stable vaccine doses at an affordable cost.
Contact
Dr Anna Malinovitch
anna.malinovitch@unimelb.edu.au
Flyer
Download flyer for more information (PDF, 845 KB)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.